Masimo on Friday Dec. 6 announced the launch of iSpO2™ Rx Pulse Oximeter with M-LNCS™ connector. The new product enables adhesive use on newborns for accurate and cost-effective screening with mobile devices in low-resource settings. The new technology has shown through studies to be the most accurate pulse oximetry during challenging conditions and has proven to help physicians in identifying life-threatening conditions in newborns. Pulse oximetry is a noninvasive method of monitoring a patient’s O2 saturation, pulse rate, and perfusion index. Globally, about 3.3 million newborns die within the first month of month of life. Pulse oximetry is critical for newborns in determining the early onset of neonatal infection, sepsis, pneumonia and birth defects among other major killers.
On Friday Dec 6. At around 2PM Masimo’s stock quickly appreciated following the announced launch of iSpO2 Rx. iSpO2 Rx’s launch is unique to its competitors in its accuracy and cost efficiency to monitor newborns in low resource environments. The device adhesive sensor attaches across the infant’s foot and has capability to wirelessly transfer test results to an iPhone, iPad, iPod touch, and soon Andriod. These key features are completely new to this category of devices. iSpO2 Rx is currently also available outside the U.S.
Moving forward iSpO2 Rx serves as the lynchpin of an ongoing collaboration with the Newborn Foundation and marks the debut of the BORN Project (Birth Oximetry Routine for Newborns). Masimo’s collaboration with the Newborn Foundation marks the first global health initiative to reduce infant mortality through access to mobile-enabled technology. Masimo’s iSpO2 Rx currently the clear leader in this category.